Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Phase II and phase III failures: 2013-2015.

Literature DB >> 27811931

Phase II and phase III failures: 2013-2015.

Richard K Harrison¹.

Abstract

Mesh：

Year: 2016 PMID： 27811931 DOI： 10.1038/nrd.2016.184

Source DB: PubMed Journal: Nat Rev Drug Discov ISSN： 1474-1776 Impact factor: 84.694

× No keyword cloud information.

2 in total

1. Trial watch: phase II and phase III attrition rates 2011-2012.

Authors: John Arrowsmith; Philip Miller
Journal: Nat Rev Drug Discov Date: 2013-08 Impact factor: 84.694

2. The year's new drugs & biologics 2015 - part II:Trends and highlights that marked a complicated year.

Authors: A I Graul; E Cruces; C Dulsat; M Tracy
Journal: Drugs Today (Barc) Date: 2016-02 Impact factor: 2.245

2 in total

100 in total

Review 1. Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities.

Authors: Donglu Zhang; Cornelis E C A Hop; Gabriela Patilea-Vrana; Gautham Gampa; Herana Kamal Seneviratne; Jashvant D Unadkat; Jane R Kenny; Karthik Nagapudi; Li Di; Lian Zhou; Mark Zak; Matthew R Wright; Namandjé N Bumpus; Richard Zang; Xingrong Liu; Yurong Lai; S Cyrus Khojasteh
Journal: Drug Metab Dispos Date: 2019-07-02 Impact factor: 3.922

2. The pharmaceutical industry needs more clinical pharmacologists.

Authors: Richard Peck
Journal: Br J Clin Pharmacol Date: 2017-08-16 Impact factor: 4.335

Review 3. Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors.

Authors: Emanuel Raschi; Fabrizio De Ponti
Journal: Front Pharmacol Date: 2019-10-24 Impact factor: 5.810

4. NMR Metabolomics Protocols for Drug Discovery.

Authors: Fatema Bhinderwala; Robert Powers
Journal: Methods Mol Biol Date: 2019

5. Organotypic Models of Lung Cancer.

Authors: Anna Pomerenke
Journal: Curr Top Microbiol Immunol Date: 2021 Impact factor: 4.291

6. Positron Emission Tomography Imaging of [¹¹ C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A.

Authors: Sarah Billington; Steven Shoner; Scott Lee; Kindra Clark-Snustad; Matthew Pennington; David Lewis; Mark Muzi; Shirley Rene; Jean Lee; Tot Bui Nguyen; Vineet Kumar; Kazuya Ishida; Laigao Chen; Xiaoyan Chu; Yurong Lai; Laurent Salphati; Cornelis E C A Hop; Guangqing Xiao; Mingxiang Liao; Jashvant D Unadkat
Journal: Clin Pharmacol Ther Date: 2019-07-22 Impact factor: 6.875

Phase II and phase III failures: 2013-2015.

1. Trial watch: phase II and phase III attrition rates 2011-2012.

2. The year's new drugs & biologics 2015 - part II:Trends and highlights that marked a complicated year.

Review 1. Drug Concentration Asymmetry in Tissues and Plasma for Small Molecule-Related Therapeutic Modalities.

2. The pharmaceutical industry needs more clinical pharmacologists.

Review 3. Strategies for Early Prediction and Timely Recognition of Drug-Induced Liver Injury: The Case of Cyclin-Dependent Kinase 4/6 Inhibitors.

4. NMR Metabolomics Protocols for Drug Discovery.

5. Organotypic Models of Lung Cancer.

6. Positron Emission Tomography Imaging of [¹¹ C]Rosuvastatin Hepatic Concentrations and Hepatobiliary Transport in Humans in the Absence and Presence of Cyclosporin A.

7. TREAP: A New Topological Approach to Drug Target Inference.

8. A microfluidic platform for functional testing of cancer drugs on intact tumor slices.

Review 9. Drug discovery effectiveness from the standpoint of therapeutic mechanisms and indications.

Review 10. Mendelian randomization in cardiometabolic disease: challenges in evaluating causality.